赛诺菲损失2.5亿!疫苗合作终止内幕曝光

生物科技馆
14 Feb

近日,赛诺菲公司宣布了一项令人失望的决定,终止了与强生公司合作的针对侵袭性大肠杆菌疾病的III期E.mbrace研究项目。这一决定是基于独立数据监测委员会在试验定期审查中的发现,即实验性疫苗在预防该疾病方面与安慰剂相比并无显著效果。赛诺菲公司在周四的新闻公告中透露,由于这一研究项目的终止,公司将记录2.5亿美元的减值费用,该费用将在其2024年第四季度资产负债表中体现。这一决定无疑给赛诺菲带来了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10